Obamacare? That’s so last month. On Capitol Hill, drug prices are now the hot topic

first_img Obamacare? That’s so last month. On Capitol Hill, drug prices are now the hot topic Senior News Editor By Erin Mershon Nov. 29, 2017 Reprints Tags Congressdrug pricespolicyWhite House Politics STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. [email protected] What’s included? What is it? Erin Mershoncenter_img GET STARTED Log In | Learn More @eemershon About the Author Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. WASHINGTON — Drug prices finally have lawmakers’ attention.After years in which the debate over Obamacare has dominated all health policymaking discussion on Capitol Hill, U.S. lawmakers are increasingly turning their attention to the prices that everyday Americans pay for their prescription drugs. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Tasos Katopodis/Getty Imageslast_img read more